| Vol. 13.13 – 8 April, 2021 |
| |
|
|
| A tumor‐microenvironment‐responsive hydrogel patch was designed to modulate the plasticity of tumor‐initiating cells in TNBC, which was insensitive to hormone‐ and HER2‐targeting. [Advanced Materials] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators showed that cyclin-dependent kinases 4 and 6 (CDK4/6i) could enhance the efficacy of T cell-based therapies, such as adoptive T cell transfer or T cell-activating antibodies anti-OX40/anti-4-1BB, in murine breast cancer models. [Cell Reports] |
|
|
|
| Using an indirect co-culture system, scientists showed that co-culture increased the invasive and migratory phenotypes of both MDA-MB-231 TNBC cells and endothelial colony-forming cells. [Oncogene] |
|
|
|
|
Researchers showed that the FDA-approved proton pump inhibitors effectively inhibited fatty acid synthase and suppressed breast cancer cell survival. [Cancer Letters] |
| | Investigators showed that monocyte chemotactic protein induced protein 1 (MCPIP1) was downregulated in 80 TNBC tissues and five TNBC cell lines compared to adjacent paracancerous tissues and one human immortalized breast epithelial cell line, while its high expression levels were associated with increased overall survival in TNBC patients. [Cell Death & Disease] |
|
|
|
| Scientists carried out the nucleosome positioning on cfDNA from 85 breast cancer patients and 85 healthy individuals and two cancer cell lines T-47D and MDA-MB-231 using low-coverage whole-genome sequencing [npj Breast Cancer] |
|
|
|
| Deoxyuridine 5′-triphosphate nucleotidohydrolase inhibition significantly sensitized TNBC cell lines to fluoropyrimidines and anthracyclines through imbalanced nucleotide pools and increased DNA damage leading to decreased proliferation and increased cell death. [npj Breast Cancer] |
|
|
|
| The mechanisms of controlling programmed death ligand-1 (PD-L1) at the transcription and protein acetylation levels in promoting breast cancer growth are presented. Overexpressed PD-L1 accelerated breast cancer growth in vitro and in vivo. [Acta Pharmacologica Sinica] |
|
|
|
|
Researchers investigated the possible effects KDM3B-ETF1 fusion gene had on breast cancer cell metastasis, invasion and its downstream signaling mediators as revealed from RNA sequence data analysis. [Cancer Gene Therapy] |
| | The authors found that nectin-4 and p95-ErbB2, but not nectin-4 and either ErbB2 or ErbB2∆Ex16, cooperatively enhanced SOX2 gene expression and cell proliferation in a suspension culture. [Scientific Reports] |
|
|
|
| The relationship between the candidate target gene DTX4 and miR-485 was validated by bioinformatics and real-time fluorescent quantitative PCR and Western blot analyses in bovine mammary epithelial cells. [Scientific Reports] |
|
|
|
|
| Investigators used breast cancer as an example of the origins of tumor heterogeneity and of tumor cell plasticity, as well as considering interclonal cooperativity and cell plasticity as sources of cancer cell heterogeneity. [British Journal of Cancer] |
|
|
|
|
| Gilead Sciences, Inc. announced that the FDA has granted full approval to Trodelvy® for adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. [Gilead Sciences, Inc.] |
|
|
|
|
| November 29 – December 1, 2021 Barcelona, Spain |
|
|
|
|
|
| North Carolina Central University – Kannapolis, North Carolina, United States |
|
|
|
| The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| UT Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
|
| Mass General Cancer Center – Boston, Massachusetts, United States |
|
|
|
|